The emergence of ciprofloxacin resistance in Shigella has shifted the attention to cephalosporins. The first occurrence of third generation cephalosporin-resistant Shigella flexneri was from France. This article reports the first case of cephalosporin-resistant S. flexneri from India. A 12-month-old child was admitted for a 20-day episode of loose stools, non-fetid, with mucus and blood. The stool sample showed the presence of blood and mucus and S. flexneri which was resistant to Ampicillin, Nalidixic acid, Ciprofloxacin, Furoxone, Ceftriaxone and sensitive only to Cefoperazone and sulbactam combination. The child was promptly admitted and treated with a combination of Cefoperazone and sulbactam. The use of this combination was met with success in the present case, and may be considered as a temporary answer to the emerging cephalosporin-resistance.
The global burden of shigellosis was estimated to be around 165 million episodes per year [1] . New disease burden estimates of shigellosis in Asia, from the International Centre for Diarrhoeal Disease Research, Bangladesh, indicate only a modest reduction in the number of infections (114 million cases) and a 90% decrease in mortality compared to the previous estimate. The majority of the disease burden is being borne by children <5 years of age [2] . Shigellosis is primarily a disease of poor, crowded communities, that do not have adequate sanitation or clean water. Among the four Shigella species, Shigella flexneri is the most commonly isolated species in the developing world [3] . Proper antimicrobial therapy not only hastens clinical recovery but also arrests the spread of the disease. The World Health Organization (WHO) currently recommends fluoroquinolones as the therapy of shigellosis. The emergence of ciprofloxacin resistance in Shigella [4] [5] [6] has shifted the attention to cephalosporins. The first occurrence of third-generation cephalosporin-resistant S. flexneri was from France [7] . This letter reports the first case of cephalosporin-resistant Shigella spp. from India.
A 12-month-old child was admitted for a 20-day episode of loose stools, non-fetid, with mucus and blood. He weighed 10 kg, which was just below the 15th percentile expected for his age according to the WHO child growth standards [8] , with no overt signs of malnutrition or any other infection. Seven months back, a similar episode was treated with ceftriaxone, though stool culture revealed no significant growth then.
The stool sample obtained during the second (present) episode showed the presence of blood and mucus, which when plated onto MacConkey agar, Xylose lysine deoxycholate agar and Deoxycholate agar (Himedia, Mumbai, India) showed the presence of a few non-lactose fermenting colonies, pink colonies and pale colonies, respectively, which were biochemically identified as Shigella spp. by the standard biochemical tests [9] , and confirmed to be S. flexneri by serotyping using type-specific antiserum (Denka-Seiken Antisera, Tokyo, Japan). Antibiotic susceptibility was determined by the Kirby-Bauer method as per Clinical Laboratory Standards Institute guidelines [10] , which showed that this isolate was resistant to Ampicillin, Nalidixic acid, Ciprofloxacin, Furoxone, Ceftriaxone and sensitive only to Cefoperazone and sulbactam combination. Subsequently, after 24 h, another sample was received from the child, which showed a repeat isolation of Ceftriaxone-resistant S. flexneri. The child was promptly admitted and treated with a combination of Cefoperazone and sulbactam. Three stool samples were sent for culture subsequently after 3 days, which did not have any further isolations of this organism. This treatment was based on the fact that a b-lactam antibiotic and a b-lactamase inhibitor combination would be able to overcome the resistance. The use of this combination was met with success in the present case, and may be considered as a 'temporary' answer to the emerging cephalosporin resistance.
Like any other Gram-negative bacteria, antimicrobial resistance is a well-described phenomenon in the genus Shigella. Though, there are quite a few reports of strains of Shigella spp. harbouring different types of Extended Spectrum b-lactamases (ESBLs) in developed and developing countries in Asia [11] [12] [13] [14] , diarrhoeal disease caused by third-generation cephalosporin-resistant Shigella spp. is relatively uncommon. Biology of the disease may be different in tropics with gut damage caused by overenthusiastic defence mechanisms or resistant enteropathogens. Shigellae are usually excreted for a few weeks after the illness. About 10% excrete them for >10 weeks and prolonged excretion tends to be common in children. Children with immunity may still have gut infections and pass the resistant bacilli to others. Nutritional deterioration, protein-losing enteropathy or intercurrent infections are issues in children with pre-existing malnutrition and post-measles state with shigellosis. The case reported did not have these complications; however, suppression of normal microbial flora by inappropriate therapy can exacerbate the infection and increase the risk of haemolytic uremic syndrome in this age group.
Initial susceptibility of Shigellae to quinolones and cephalosporins was a period of optimism, but resistant strain travels unseen. The laboratory control for this enteral infection cannot thus be overemphasized.
